AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

AAM Podcast: Build Back Better Hurts Patient Access to Generics and Biosimilars

On the featured All Access Podcast, AAM CEO Dan Leonard convenes industry experts from Teva, Fresenius Kabi and policy expert Kurt Karst to explore why the Inflation Reduction Act (f/k/a Build Back Better) is still bad for America's patients.

Listen to Podcast
Take Action on Build Back Better Now!

Congress is actively considering prescription drug reforms included in the Inflation Reduction Act (f/k/a Build Back Better) that would undermine access to the affordable FDA-approved generic and biosimilar medicines that millions of seniors rely on to manage their health. Send a message to your lawmaker now!

Take Action
Who’s Profiting from Your Prescription?

Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.

Learn More
What Are GDUFA and BsUFA User Fees?

Watch this this video to learn more about how the Generic Drug User Fee Amendments (GDUFA) and Biosimilar User Fee Act (BsUFA) help to get more generic and biosimilar medicines to patients more quickly.
Watch Video
AAM Calls on FTC to Investigate PBM Business Practices

“A distinct set of PBM business practices have resulted in higher prices and delayed access to generics and biosimilars for patients,” said AAM CEO Dan Leonard.

Read Press Release
Generic Medicines Are Saving Your State Billions

In 2020, generic and biosimilar medicines saved America's patients $338 billion. Find out how much your state saved with our interactive savings map.

View Interactive Map
Prescription for State Savings

State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.

Learn More
AAM Voices of Access

Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

View Report

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Senior patient picking up medicines at a pharmacy

Jul 20, 2022 | Craig Burton

Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly

A pharmacological manufacturing and bottling factory in a bright laboratory environment

Jul 20, 2022 | Craig Burton

Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers

Percent of Patients Who Paid the Full Cost of a Generic at Least Once, 2017 and 2020

Jul 12, 2022 | Monét Stanford

Despite Enrollment In Medicare Prescription Drug Coverage, Over Half of All Seniors Pay Full Cost for Many Generic Drugs

Misguided Drug Pricing Reform

Jul 6, 2022 | Allen Goldberg

AAM Statement on BBB 2.0

AAM All Access Podcast

Jul 1, 2022 | Dan Leonard

AAM All Access Podcast: Drug Shortages and the U.S. Supply Chain

Jun 13, 2022 | Erica Klinger

AAM Code of Business Ethics